Our clinical studies

Randomised, double-blind, placebo-controlled dose-effect study of V0114 (2.5, 5, 7.5 and 10 mg) versus mequitazine 10 mg and placebo in the treatment of seasonal allergic rhinitis

Randomised Phase II Study comparing, as first-line chemotherapy, single-agent Oral Vinorelbine administered with two different schedules in patients with Advanced Breast Cancer

Efficacy of the topic RV3131A-HC3221 in the prevention of polymorphic light eruption

Phase II study assessing the maintenance treatment with vinflunine after first-line therapy with gemcitabine and cisplatin in patients with advanced or metastatic transitional cell carcinoma of the urothelial tract

A multicenter, randomized, open-label, 2-arm, Phase II trial with a safety lead-in phase evaluating the combination of encorafenib and cetuximab versus irinotecan/cetuximab or infusional 5-fluorouracil (5-FU)/folinic acid (FA)/irinotecan (FOLFIRI)/cetuximab in Chinese patients with BRAFV600E mutant metastatic colorectal cancer.

Efficacy study of Ciclopiroxolamine 1% foam (DC115 GM 02A) versus Ciclopiroxolamine 1.5% shampoo (SEBIPROX®) in the treatment of moderate seborrheic dermatitis of the scalp

Phase II Study of Navelbine oral and Arimidex as neo-adjuvant treatment in post-menopausal women with locally advanced breast carcinoma

A double-blind placebo controlled study of 1g, 2g and 4g V0251 efficacy and tolerance in vestibular neuritis

Randomised phase II study evaluating, as first-line chemotherapy, weekly oral vinorelbine as a single-agent versus weekly paclitaxel as a single-agent in estrogen receptor positive, HER2 negative patients with advanced breast cancer

Phase II trial of oral vinorelbine in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) positive mutation after failure or resistance to treatment with Tyrosine Kinase Inhibitors (TKI) in first line

Evaluation of the effect of 6 months treatment with V0191 on symptoms changes in patients with Mild Cognitive Impairment. Multicentre, randomised, double-blind, placebo-controlled study in parallel groups

Phase II study of oral vinorelbine in combination with capecitabine in metastatic breast cancer patients previously treated with anthracyclines and taxanes

Randomised phase II study of the combination of oral vinorelbine with capecitabine versus gemcitabine in combination with paclitaxel versus gemcitabine in combination with docetaxelchemotherapy in patients with metastatic breast cancer.

Effect of 3-month treatment with F2695 (75mg OD) on improving functional recovery of patients with ischemic stroke. A multicenter, randomised, double-blind, parallel-group, placebo-controlled study

Phase 2, open-label, single arm, multicenter study of Encorafenib, Binimetinib plus Cetuximab in subjects with previously untreated BRAFV600E -mutant metastatic colorectal cancer

Exploratory study of besipirdine efficacy and safety in male patients with persistent stress urinary incontinence after radical prostatectomy

Phase II trial of oral vinorelbine in combination with capecitabine and trastuzumab as first line therapy in women with previously untreated HER2 positive metastatic breast cancer

Randomised phase II trial of oral vinorelbine and cisplatin followed by maintenance with single agent oral vinorelbine versus gemcitabine and cisplatin followed by maintenance with single agent gemcitabine in first line Locally Advanced or Metastatic Non-Small-Cell Lung Cancer patients with squamous histological type

Randomised phase II study of the combination of oral vinorelbine with capecitabine versus a sequential regimen of oral vinorelbine and capecitabine versus the combination of docetaxel and capecitabine...

Phase II trial of oral vinorelbine in combination with capecitabine as first line therapy in women with previously untreated HER2 negative metastatic breast cancer